Accumulation and deposition of β-amyloid (Aβ) peptides in the cerebral cortex is believed to be an early and central process in the pathogenesis of Alzheimer's disease (AD). The Aβ peptides are generated from sequential proteolytic cleavage of the amyloid precursor protein (APP) by β-and γ-secretases, which are therefore considered important targets for therapeutic intervention. Molecular cloning (1-3) and crystallographic studies (4) have unequivocally established β-secretase as an aspartyl protease. However, the identity of γ-secretase remains elusive.
It is known that transmembrane proteins presenilin 1 (PS1) and presenilin 2 (PS2) are essential for intramembranous proteolytic γ-cleavage of APP (5) and a few other γ-secretase substrates such as Notch (6) (7) (8) (9) and ErbB4 (10) . Evidence suggests that presenilins may have direct catalytic activity (11, 12) , but recent reports indicate that this activity requires interactio ns between presenilins and other proteins, such as nicastrin (13) , and co-fractionates with a very high molecular weight complex (14) . Mature presenilins themselves form subunit heterodimers between the N-terminal and C-terminal fragments, which are generated from endoproteolytic cleavage of the full-length presenilin (15, 16) . This complex membrane-bound molecular organization has hindered efforts to purify and reconstitute γ-secretase activity.
In the absence of purified enzyme and crystal structures, inhibition studies have played a prominent role in the understanding of the nature of γ-secretase. The γ-secretase activity is sensitive to aspartyl protease transition state analogs such as the hydroxylethylene isosteres pepstatin (17) (18) (19) and L685458 (20) , typical aspartyl protease transition state inhibitors. Peptidomimetics containing a difluoro alcohol group, another by guest on http://www.jbc.org/ Downloaded from aspartyl protease transition state isostere, are also potent inhibitors of γ-secretase (21) .
Given these results, it has been hypothesized that like β-secretase, γ-secretase is an aspartyl protease (17) (18) (19) (20) (21) (22) . Recent pepstatin-derived affinity chromatography of PS1 (23) , photo affinity labeling of PS1 with transition state analog L685458 (12) , and chemical affinity labeling of PS1 with difluoro peptidomimetics (24) further support γ-secretase as an aspartyl protease, and have led to the tentative identification of presenilins as the catalytic components of γ-secretase.
Although these transition state analogs have been extensively used as tools to probe the structure and mechanism, as well as the biochemical and cellular functions, of γ-secretase, the mechanisms of γ-secretase inhibition by these compounds have not been elucidated. Among potent and specific γ-secretase inhibitors are also a number of small molecules of different structural classes, such as sulfonamides (25) and benzodiazepines (26) . It is an intriguing question whether these non-aspartyl protease isosteres would inhibit γ-secretase by the same mechanism as the transition state isosteres. Elucidating the inhibitory mechanisms of these different classes of inhibitors may provide important insights into the catalytic mechanism of γ-secretase and help in the design of novel drugs.
Here we report the results from inhibition of solubilized cell-free human γ-secretase by pepstatin A methylester (PME), L685458, sulfonamides 1 and 2, and benzodiazepines 3 and 4 ( Figure 1) . Unexpectedly, the transition state analogs PME and L685458 inhibited γ-secretase by a linear non-competitive inhibition mechanism, suggesting that substrate can bind to the enzyme while the active site is occupied by transition state analogs. Similar non-competitive inhibition was also observed for the non-aspartyl protease isosteres 1 -4. To our knowledge, this is the first example of This fragment was cloned into the vector pET-21a (+). The insert contained a stop codon to prevent the carboxyl terminus of C100 from fusing with the His-tag of the vector. [S]
where V m and K m are maximum velocity and the Michaelis-Menten constant, respectively, and S is substrate. Inhibition data were fit to the following equations, respectively, for competitive, non-competitive or uncompetitive inhibition:
and
where K is is the inhibitor constant for inhibitor binding to the free enzyme and K ii is the inhibition constant for inhibitor binding to the ES complex. To analyze whether inhibition is linear, the double reciprocal plots obtained at different inhibitor concentrations were fit to a linear equation and the slope or intercept were then reanalyzed either by a linear equation:
where a and b are constants, or by a second order polynomial:
where c is also a constant.
RESULTS

Kinetics of solubilized γ-secretase.
The primary goal of this study was to elucidate the inhibition mechanisms of known γ-secretase transition state analogs PME and L685458 and small molecule inhibitors sulfonamides and benzodiazepines. As γ-secretase is quite complex structurally and has never been purified to homogeneity, it is by guest on September 1, 2017
http://www.jbc.org/ Downloaded from crucial to characterize carefully the substrate kinetics in order to provide a framework for inhibition studies. The substrate used in this study was C100, a recombinant protein constructed according to the sequence of β-secretase generated C-terminal fragment of APP (CTFβ), a natural substrate of γ-secretase. All the reactions were run at pH 6.5, the pH optimum under the reaction conditions employed in this study (data not shown). The reaction of γ-secretase with C100 was monitored by following the production of Aβ40, the major product of the γ-secretase reaction, using the IGEN ECL technology. The initial rate was calculated as the slope of the reaction progress curve for Aβ40 production. The total turnover was < 1% even at the lowest substrate concentration (0.05 µM), so there was essentially no substrate depletion. The total product formed was < 1 nM, and this product concentration was in the linear range of Aβ40 detection as judged from the Aβ40 standard curves (data not shown). The progress curves at pH 6.5 were linear for at least 2 h (Figure 2A ), suggesting the enzyme was stable during the experiments. This method for determination of initial rates was much more accurate than end point measurements and was used to perform all the kinetic experiments described in this paper.
As shown in Figures 2B and 2C , the initial rate of the solubilized γ-secretase as a function of C100 concentration followed a typical hyperbola. This, as well as the apparent linearity in the progress curves for initial rate measurements as stated above, suggested that the reactions followed a typical steady state kinetic mechanism. The kinetic constants were calculated by fitting the initial rates to the Michaelis-Menten by PME (data not shown). As a result of these data, we examined in greater detail the effect of inhibitor concentration on the slope and intercept of the double reciprocal plot by employing a total of eight inhibitor concentrations in a separate kinetic experiment, reasoning that the slope replot as a function of inhibitor concentration would be curved.
A parabolic slope replot but a linear intercept replot would indicate that the inhibitor, while binding at the catalytic site as a transition state analog is expected to do, may also bind at an allosteric site, thereby causing the observed non-competitive inhibition (Appendix). On the other hand, linear slope and intercept replots would indicate that the inhibitor binds at a single, non-competitive binding site (31, 32) . As shown in Figure 3 , the double reciprocal plot of inhibition by PME ( Figure 3A ) again clearly indicated noncompetitive inhibition. Importantly, both the slope ( Figure 3B ) and intercept ( Figure 3C) replots were linear, consistent with a pure non-competitive model where just one inhibitor binds to enzyme, as illustrated by eq 7: 
The value of K is , which is the inhibition constant for inhibitor binding to free enzyme (E), and the value of K ii , whic h is the inhibition constant for inhibitor binding to the ES complex, were similar ( Table 1 ), suggesting that there was little interaction between the substrate C100 and PME in the ternary complex and minimal conformational change that would affect the inhibitor binding upon substrate binding or vice versa. To rule out the possibility that the apparent non-competitive inhibition might arise from artifacts due to substrate aggregation at room temperature, the kinetic experiments were repeated at 37 o C. As shown in Figure 4A , the kinetic pattern for PME obtained at 37 o C was not different from that which was obtained at 22 o C ( Figure 3A) , although the inhibition constants were slightly higher at high temperature ( Table 1 ). The linear progress curves in the presence of PME (data not shown), and the near total recovery of enzyme activity from dilution of enzyme-PME complex (data not shown), ruled out the possibility of time-dependence or irreversible inhibition of γ-secretase by PME as the cause of the observed non-competitiveness. Taken together, these data indicate that PME is a bona fide linear non-competitive inhibitor of γ-secretase.
Non-competitive inhibition of γ-secretase by L685458, sulfonamides, and
benzodiazepines. To determine if this type of non-competitive inhibition is PMEspecific, we investigated the inhibition kinetics for three other types of γ-secretase inhibitors. L685458, another aspartyl protease transition state analog, also displayed a non-competitive inhibition pattern, as shown in Figure 4B . The data obtained for four non-transition state inhibitors, two sulfonamides (1, and 2) and two benzodiazepines (3 and 4), also indicated non-competitive inhibition ( Figure 5 ). As observed for PME, the values of K is were also quite similar to the values of K ii for each of these compounds (Table 1) , suggesting minimal interaction between substrate and inhibitor. These data demonstrate that the non-competitive inhibition kinetics observed with γ-secretase is not restricted to a certain class of compounds but is quite common among γ-secretase inhibitors.
DISCUSSION
Several different structural classes of γ-secretase inhibitors have been extensively
used as tools for biochemical and functional studies of γ-secretase. In this study, the mechanisms of γ-secretase inhibition by transition state analogs PME and L685458 and non-transition state inhibitors sulfonamides and benzodiazepines were investigated.
Surprisingly, both the transition state isosteres and the non-transition state inhibitors displayed linear non-competitive inhibition.
The simplest interpretation of the linear non-competitive inhibition by PME is that PME binds to a non-catalytic, allosteric site of γ-secretase, which can be adequately described by a simple kinetic scheme as shown by eq 7. It is known that γ-secretase is a high molecular weight, macromolecular complex (13, 14) . This complex contains at least two functional units, presenilin (1 or 2) and nicastrin (13 kinetics.
Yet to be proven, evidence exists to suggest strongly that γ-secretase is an aspartyl protease (12, (17) (18) (19) (20) (21) (22) (23) (24) . Therefore, the issue with this model of PME or L685458 binding to an allosteric site is the binding of a transition state analog exclusively at a non-catalytic site. Consistent with the inhibitor-binding to a site that is different from the substratebinding site, Wolfe and co-workers recently reported that CTFα, a natural substrate of γ-secretase, could be co-purified with PS1 from an aspartyl protease inhibitor affinity column (33) . To interpret this result, they proposed that substrate first binds to a docking site on the enzyme, and then moves to the catalytic site where it is subsequently cleaved ( Figure 6A ). The inhibitor, however, can bind directly at the catalytic site, thus explaining the co-purification of PS1 and CTFα by the transition-state analog-based affinity chromatography. This model is consistent with the non-competitive kinetic inhibition results presented in this study. Alternatively, the initial substrate binding is not docking, but a process that anchors a tail (for example, the N-or C-terminus) of the substrate. Then, a conformational change of substrate bound at the anchor site may occur, perhaps swinging the scissile bond into the catalytic site for cleavage ( Figure 6B ).
Several other possibilities exist that may also explain the non-competitive inhibition kinetics. For example, inhibitor may bind to an intermediate on the catalytic pathway of the substrate, which would result in non-competitive inhibitio n. However, a substrate-derived intermediate, such an acyl enzyme complex, is not expected to be present along the catalytic pathway if γ-secretase is indeed an aspartyl protease. Another possibility would be that the active site is shaped as a channel with the docking site being located at the entrance and the catalytic site at the end. The catalytic site would be accessible to inhibitor while a substrate molecule is bound at the opening of the channel.
The substrate binding process may also involve docking proteins which deliver specific substrates in much the same way E2 conjugases introduce specific substrates to E3
ligases (34) . The docking proteins would have specific binding sites for the substrate, and would share a common binding domain for γ-secretase.
These putative mechanisms are attractive in light of the data presented in this paper, explaining the non-competitive inhibition kinetics of known aspartyl protease inhibitor isosteres PME and L685458, and providing additional sites of interactions for non-transition state inhibitors such as the sulfonamides and benzodiazepines that also 
APPENDIX
Assuming fast equilibria for the substrate and inhibitor bindings and that the inhibitor binds to both the substrate binding site and an allosteric site according to the following mechanism:
The initial rate equation is then given by eq A2:
Thus, the slope and intercept replots will be, respectively, a parabolic and linear function of [I]:
and properties for inhibition of solubilized human γ-secretase by PME, L685458, 1, 2, 3, and 4 at pH 6.5. 
